Breakthrough COVID-19 Infections after Booster SARS-CoV-2 Vaccination in a Greek Cohort of People Living with HIV during the Delta and Omicron Waves.

Autor:	Protopapas K; 4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, 1 Rimini Str., Chaidari, 12462 Athens, Greece., Thomas K; 4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, 1 Rimini Str., Chaidari, 12462 Athens, Greece., Moschopoulos CD; 4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, 1 Rimini Str., Chaidari, 12462 Athens, Greece., Oktapoda E; 4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, 1 Rimini Str., Chaidari, 12462 Athens, Greece., Marousi E; 4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, 1 Rimini Str., Chaidari, 12462 Athens, Greece., Marselou E; 4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, 1 Rimini Str., Chaidari, 12462 Athens, Greece., Stamoulis N; 4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, 1 Rimini Str., Chaidari, 12462 Athens, Greece., Filis C; 4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, 1 Rimini Str., Chaidari, 12462 Athens, Greece., Kazakou P; 4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, 1 Rimini Str., Chaidari, 12462 Athens, Greece., Oikonomopoulou C; 4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, 1 Rimini Str., Chaidari, 12462 Athens, Greece., Zampetas G; 4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, 1 Rimini Str., Chaidari, 12462 Athens, Greece., Efstratiadou O; 4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, 1 Rimini Str., Chaidari, 12462 Athens, Greece., Chavatza K; 4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, 1 Rimini Str., Chaidari, 12462 Athens, Greece., Kavatha D; 4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, 1 Rimini Str., Chaidari, 12462 Athens, Greece., Antoniadou A; 4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, 1 Rimini Str., Chaidari, 12462 Athens, Greece., Papadopoulos A; 4th Department of Internal Medicine, University General Hospital Attikon, Medical School, National and Kapodistrian University of Athens, 1 Rimini Str., Chaidari, 12462 Athens, Greece.
Jazyk:	angličtina
Zdroj:	Biomedicines [Biomedicines] 2024 Jul 19; Vol. 12 (7). Date of Electronic Publication: 2024 Jul 19.
DOI:	10.3390/biomedicines12071614
Abstrakt:	Introduction: Currently approved SARS-CoV-2 vaccines have been proven effective in protecting against severe COVID-19; however, they show variable efficacy against symptomatic infection and disease transmission. We studied the breakthrough COVID-19 infection (BTI) after booster vaccination against SARS-CoV-2 in people living with HIV (PWH). Methods: This was a retrospective, single-center, descriptive cohort study involving PWH, who were followed in the HIV Clinic of "Attikon" University Hospital in Athens, Greece. A BTI was defined as a case of laboratory-confirmed COVID-19 occurring at least 14 days after the third (booster) vaccine dose. Results: We studied 733 PWH [males: 89%, mean age: 45.2 ± 11.3 years, mean BMI: 26.1 ± 4.1, HIV stage at diagnosis (CDC classification): A/B/C = 80/9/11%, MSM: 72.6%] with well-controlled HIV infection. At least one comorbidity was recorded in 54% of cases. A history of ≥1 vaccination was reported by 90%, with 75% having been vaccinated with ≥3 vaccines. Four hundred and two (55%) PWH had a history of COVID-19 and 302 (41.2%) had a BTI, with only 15 (3.7%) needing hospitalization. Only one patient was admitted to the ICU, and no death was reported. Regarding BTI after booster dose, increased age (OR = 0.97, 95% CI: 0.96-0.99, per 1-year increase), and COVID-19 infection prior to booster dose (OR = 0.38, 95% CI: 0.21-0.68) were associated with a lower likelihood for BTI, whereas higher BMI (OR = 1.04, 95% CI: 1.01-1.08) and MSM as a mode of HIV transmission were associated with increased risk (OR = 2.59, 95% CI: 1.47-4.56). The incidence rate of total COVID-19 and BTI followed the epidemic curve of the general population, with the highest incidence recorded in June 2022. Conclusions: A significant proportion of PWH with well-controlled HIV infection experienced a BTI, with the majority of them having mild infection. These data, which include the period of Omicron variant predominance, confirm the importance of vaccination in the protection against severe COVID-19.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu